Fig. 1

OPTN expression is downregulated in AD patients and APP/PS1 transgenic mice. A–D Transcriptome data of the entorhinal cortex, hippocampus, frontal cortex, and temporal cortex in AD patients were analyzed after normalization. E–H Nine-month-old APP/PS1 transgenic mice were anesthetized and euthanized to obtain the cerebral cortex and hippocampus. E Expression of OPTN in the cerebral cortex and hippocampus of APP/PS1 transgenic mice was detected by qRT-PCR using GAPDH as an internal control. F The protein level of OPTN in the cerebral cortex and hippocampus of APP/PS1 transgenic mice was assessed by western blotting using β-actin as an internal control. G ImageJ software was used to semiquantitatively analyze the fold change of OPTN relative to β-actin. H WT or APP/PS1 Tg mice were double-stained for Iba1 (green) and OPTN (red). I Expression of OPTN in microglia in the cortex and hippocampus of APP/PS1 transgenic mice at 9 months of age was detected by flow cytometry. The data represent the means ± S.E. of independent experiments. APP/PS1 transgenic mice were compared with WT mice *P < 0.05, **P < 0.01